EDIT-102

EDIT-102 is an experimental CRISPR-based genome editing medicine designed for the treatment of Usher Syndrome Type 2A (USH2A), a genetic condition characterized by hearing loss from birth and progressive vision loss due to retinitis pigmentosa. Developed by Editas Medicine, the therapy utilizes CRISPR/Cas9 technology to target and repair mutations in the USH2A gene, specifically aiming to restore the production of functional usherin protein in the retina. The program was originally part of a strategic alliance with Allergan (later acquired by AbbVie), but Editas Medicine regained full global rights to the asset in 2020. EDIT-102 is intended for subretinal administration to directly modify the genomic sequence in photoreceptor cells.